(NASDAQ:CYAN) A Perfect Storm / Tipping Point At Becoming The Dominant Neutra-Pharmaceutical
December 17, 2011
– Comments (6) |
RELATED TICKERS: CYAN
, BMY
, ABT
(NASDAQ:CYAN) A Perfect Storm/Tipping Point At Becoming The Dominant Neutra-Pharmaceutical by itself or as a high growth division for BMY, ABT, et al?
So....the obvious question and elephant in the room is:
Given CYAN's BioAstin's now confirmed superiority over any competitor's product and Worldwide buzz viz-a-viz FDA approval, Scientific studies , Dr. OZ, Dr. Mercola...WHY hasn't CYAN management engaged in a strategic alliance(s) with ANY Fortune 200 to distribute and advertise on national television, HULU, Internet, et al with the greatest vitamin in history and existence with 1. MD Formulas' OmegaAstin 2. all obvious line-extensions DermaAstin, JointAstin and or with a newly created line with (NYSE:ABT) Fortune #69, (NYSE:BMY) Fortune #131, et al ? This is a slam dunk and, again, goes to management depth. The timing would simply be perfect(.)
Reference:
(November 17, 2011) Cyanotech Q2 2012 Ending September 30, 2011 Numbers.